We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » APOTEX'S SALES OF GENERIC PAXIL SLASHED BY GSK-AUTHORIZED VERSION
The item has been added to your shopping cart.
APOTEX'S SALES OF GENERIC PAXIL SLASHED BY GSK-AUTHORIZED VERSION
April 15, 2004
Generic firm Apotex said its version of GlaxoSmithKline’s antidepressant Paxil (paroxetine HCl) garnered sales of about $150 million to $200 million during its 180-day exclusivity period — a return far smaller than what it had expected because of an authorized generic competitor.